

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Follicular Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding the Phase III RELEVANCE study comparing rituximab with chemotherapy (R-chemo) to lenalidomide/rituximab (R²) followed by maintenance rituximab for patients with previously untreated follicular lymphoma (FL)?**
 - a. Progression-free survival (PFS) outcomes were significantly better with R²
 - b. PFS outcomes were significantly better with R-chemo
 - c. PFS outcomes were similar with R² and R-chemo**
- 2. Results from the induction phase of the Phase IIIb MAGNIFY trial evaluating R² followed by maintenance R² or rituximab alone for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma demonstrated durable responses with R² in which of the following patient populations?**
 - a. Rituximab-refractory disease
 - b. Double-refractory disease
 - c. Early relapse
 - d. None of the above
 - e. All of the above**
- 3. Which of the following observations was reported in the Phase IV GAZELLE trial evaluating obinutuzumab short duration infusion (SDI) for patients with previously untreated advanced FL?**
 - a. The majority of patients experienced a Grade 3 or higher infusion-related reaction (IRR) with obinutuzumab SDI in cycle 2
 - b. A minority of patients experienced a Grade 3 or higher IRR with obinutuzumab SDI in cycle 2
 - c. No patients experienced a Grade 3 or higher IRR with obinutuzumab SDI in cycle 2**
- 4. What was reported in the Phase I/Ib GO29781 study regarding overall and complete response rates with the investigational CD20 x CD3 T-cell engaging bispecific agent mosunetuzumab for patients with R/R FL who received at least 2 prior systemic therapies?**
 - a. High overall response rate with more than 50% complete responses**
 - b. High overall response rate with minimal complete responses
 - c. 50% overall response rate with minimal complete responses
 - d. 50% overall response rate but no complete responses
 - e. Low overall response rate with no complete responses